A mutation in the KIF1B tumour suppressor was detected (WES) only after chemotherapy in patient CB1008, which was confirmed by targeted ultra-deep sequencing, suggesting that this mutation occurred de novo during therapy (Fig. 2a and Supplementary Fig. 2f). Here, KIF1B is linked to neoplasm.